CWBR - CohBar, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.5000
-0.1000 (-6.25%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.6000
Open1.6400
Bid1.2000 x 3000
Ask1.6200 x 1000
Day's Range1.4000 - 1.6000
52 Week Range1.3000 - 5.5500
Volume34,518
Avg. Volume120,090
Market Cap64.292M
Beta (3Y Monthly)2.08
PE Ratio (TTM)N/A
EPS (TTM)-0.3470
Earnings DateApr 1, 2019 - Apr 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire

    CohBar Reports Second Quarter 2019 Financial Results and Business Update

    Company to host conference call and webcast today, August 7th, at 5:00 p.m. EDT MENLO PARK, Calif., Aug. 07, 2019 -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage.

  • GlobeNewswire

    CohBar to Announce 2019 Second Quarter Financial Results and Provide Business Update on August 7, 2019

    CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that the company will release its second quarter 2019 financial results after the market closes on Wednesday, August 7, 2019.  Management will host a conference call with a slide presentation at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on the company’s business.

  • GlobeNewswire

    CohBar poster available on preclinical results showing efficacy of a new family of mitochondria based therapeutics in a type 2 diabetes model as presented at the American Diabetes Association 79th Scientific Sessions

    CohBar, Inc. (CWBR), a clinical stage biotechnology company focused on developing mitochondria based therapeutics to treat age-related diseases, today announced its poster presentation is available on the preclinical data on a family of novel peptide analogs related to the mitochondrially encoded peptide CB5064 which are under development as a potential source of treatments for type 2 diabetes, at the American Diabetes Association 79th Scientific Sessions held June 7-11, 2019 in San Francisco, California.

  • GlobeNewswire

    CohBar to Hold 2019 Annual Shareholder Meeting and Investor Update June 18, 2019

    MENLO PARK, Calif., June 05, 2019 -- CohBar, Inc. (NASDAQ: CWBR) a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related diseases.

  • GlobeNewswire

    CohBar to Present Data on Novel Analogs of a Mitochondrially Encoded Peptide with Beneficial Effects in an Animal Model of Type 2 Diabetes at the American Diabetes Association 79th Scientific Sessions

    CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related diseases and extend healthy lifespan, today announced that it will present its data on a family of novel analogs of a peptide encoded in mitochondrial DNA showing  beneficial effects on glucose tolerance and weight loss in an animal model of type 2 diabetes. The poster will be presented at the American Diabetes Association, 79th Scientific Sessions at 12:00 PM on June 9, in San Francisco, California.

  • GlobeNewswire

    CohBar Reports First Quarter 2019 Financial Results and Business Update

    MENLO PARK, Calif., May 07, 2019 -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related.

  • ACCESSWIRE

    CohBar, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 7, 2019 / CohBar, Inc. (NASDAQ: CWBR ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 7, 2019 at 5:00 PM Eastern Time. ...

  • GlobeNewswire

    CohBar Appoints Steven B. Engle as Chief Executive Officer

    CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases and extend healthy lifespan, announced today that it has appointed Steven B. Engle as its Chief Executive Officer, effective May 15, 2019. CohBar’s interim Chief Executive Officer Dr. Philippe Calais will continue to serve on the company’s Board, a position he has held since June 2018. “Steven is a highly accomplished healthcare executive, and we are very happy to have him leading the CohBar team at this important time in the company’s evolution,” said Albion J. Fitzgerald, Chairman of the Board of Directors.

  • GlobeNewswire

    CohBar to Announce 2019 First Quarter Financial Results and Provide Business Update on May 7, 2019

    MENLO PARK, Calif., April 26, 2019 -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related.

  • GlobeNewswire

    CohBar Announces Key Opinion Leader Conference Call and Webcast

    CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced that the Company will host a Key Opinion Leader conference call and webcast on May 2, 2019 featuring thought leaders who will discuss the role of mitochondria in health and aging, and mitochondrial-derived peptides (MDPs) as a novel source of potential therapeutics for a host of major age-related diseases. CohBar's management team will also provide an overview of the company’s mitochondria based therapeutics platform, from identification of peptides encoded within the mitochondrial genome to discovery and development of novel peptide analogs with therapeutic potential, and its lead clinical program targeting NASH and obesity.

  • GlobeNewswire

    CohBar Announces the Appointment of David Greenwood to its Board of Directors

    CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases and extend healthy lifespan, today announced the appointment of David Greenwood to its Board of Directors.

  • GlobeNewswire

    CohBar Reports Fourth Quarter 2018 Financial Results and Provides Business Update

    MENLO PARK, Calif., March 18, 2019 -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related.

  • GlobeNewswire

    CohBar to Announce 2018 Fourth Quarter Financial Results and Host Conference Call on March 18, 2019

    MENLO PARK, Calif., March 04, 2019 -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related.

  • GlobeNewswire

    CohBar Announces the Appointment of Dr. Phyllis Gardner to its Board of Directors

    CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced the appointment of Phyllis Gardner, M.D., to its Board of Directors and to the Board’s Audit Committee. “Dr. Gardner’s very broad and deep expertise in medicine, biotechnology, and corporate investing and governance is an ideal skill set for the CohBar Board as we strategically advance our portfolio and pipeline of mitochondrial peptides and disease targets,” said Albion Fitzgerald, Chairman of the Board.

  • GlobeNewswire

    CohBar Appoints Philippe P. Calais, Pharm.D., Ph.D. as Interim Chief Executive Officer

    CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that it has appointed Philippe P. Calais, Pharm.D., Ph.D. as its interim Chief Executive Officer, effective December 7, 2018.  Dr. Calais will continue to serve on the company’s Board of Directors, which he joined in June 2018.

  • GlobeNewswire

    Research Report Identifies Equinix, Universal Electronics, LHC Group, Cohbar, Amgen, and Aetna with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Nov. 29, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire

    CohBar Founder Dr. Nir Barzilai Awarded the 2018 Fondation IPSEN Longevity Prize

    CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced that company co-founder Dr. Nir Barzilai has been awarded the Fondation IPSEN Longevity Prize during the 22nd Geriatric Society of America meeting, which was held on November 17 in Boston. The IPSEN international jury, chaired by Professor Thomas Kirkwood, Professor Emeritus at Newcastle University Institute for Aging and Health, and Professor at the University of Copenhagen Center for Healthy Aging, unanimously selected Dr. Barzilai for his pioneering research on the molecular, genetic and hormonal mechanisms that can extend human longevity.

  • GlobeNewswire

    CohBar Reports Third Quarter 2018 Financial Results and Provides Business Update

    Will Host Conference Call on November 14, 2018 at 5:00 p.m. Eastern Time MENLO PARK, Calif., Nov. 14, 2018 -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology.

  • GlobeNewswire

    CohBar Co-Founder and Scientific Advisor Dr. David Sinclair Named as one of TIME Magazine’s Health Care 50

    CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced that co-founder and scientific advisor Dr. David Sinclair is featured among TIME Magazine’s Health Care 50, a profile of fifty people changing healthcare in 2018. The profile cites Dr. Sinclair’s ongoing work in addressing and even reversing typical signs of aging, including high blood pressure, weight gain and decreased metabolism. Dr. Sinclair was also featured as one of TIME Magazine’s 100 Most Influential People in 2014.

  • GlobeNewswire

    CohBar Provides Update on CB4211 Clinical Trial

    CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today the Phase 1 clinical study of CB4211, its lead MBT candidate under development as a potential treatment for non-alcoholic steatohepatitis (NASH) and obesity, has been temporarily suspended in order to address mild injection site reactions that have been unexpectedly persistent. “Patient safety is very important to us and is also the primary objective of our CB4211 Phase 1 clinical trial,” said Simon Allen, CohBar CEO.

  • GlobeNewswire

    CohBar to Announce 2018 Third Quarter Financial Results and Host Conference Call on November 14, 2018

    MENLO PARK, Calif., Oct. 31, 2018 -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related.